• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[继发性骨质疏松症。糖皮质激素诱导的骨质疏松症:椎体骨折的骨密度阈值]

[Secondary osteoporosis. Glucocorticoid-induced osteoporosis: Threshold of bone mineral density for vertebral fracture].

作者信息

Soen Satoshi

机构信息

Kinki University School of Medicine, Nara Hospital, Department of Orthopaedic Surgery and Rheumatology.

出版信息

Clin Calcium. 2007 Mar;17(3):399-402.

PMID:17339745
Abstract

The use of systemic corticosteroids is one of independent risk factors with bone mineral density (BMD) for fractures. The prior and current exposure to corticosteroids confers an increased risk of fracture that is of substantial importance beyond that explained by the decrease of BMD. Cut-off value of lumbar BMD for vertebral fractures was 80% of young adult mean in Japanese patients. For management of glucocorticoid-induced osteoporosis, we have to concern about all risk factors of fracture including BMD and use the evidence-based guideline.

摘要

全身使用糖皮质激素是导致骨折的骨密度(BMD)独立危险因素之一。既往和当前使用糖皮质激素会增加骨折风险,这一风险的重要性远超过因骨密度降低所解释的部分。在日本患者中,椎体骨折的腰椎骨密度临界值为年轻成人平均值的80%。对于糖皮质激素诱导的骨质疏松症的管理,我们必须关注包括骨密度在内的所有骨折危险因素,并采用循证指南。

相似文献

1
[Secondary osteoporosis. Glucocorticoid-induced osteoporosis: Threshold of bone mineral density for vertebral fracture].[继发性骨质疏松症。糖皮质激素诱导的骨质疏松症:椎体骨折的骨密度阈值]
Clin Calcium. 2007 Mar;17(3):399-402.
2
Vertebral fracture and bone mineral density in women receiving high dose glucocorticoids for treatment of autoimmune diseases.接受高剂量糖皮质激素治疗自身免疫性疾病的女性的椎体骨折与骨密度
J Rheumatol. 2005 May;32(5):863-9.
3
[Guidelines for the treatment of glucocorticoid-induced osteoporosis and their future problems].[糖皮质激素性骨质疏松症的治疗指南及其未来问题]
Clin Calcium. 2006 Nov;16(11):1788-96.
4
[Glucocorticoid induced osteoporosis].[糖皮质激素性骨质疏松症]
Orthopade. 2007 Apr;36(4):381-8; quiz 389-90.
5
Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options.糖皮质激素性骨质疏松症:病理生理学与治疗选择综述
Minerva Med. 2008 Feb;99(1):23-43.
6
[Management of glucocorticoid-induced osteoporosis].[糖皮质激素性骨质疏松症的管理]
Clin Calcium. 2005 Apr;15(4):616-24.
7
An update on glucocorticoid-induced osteoporosis.糖皮质激素性骨质疏松症的最新进展。
Curr Opin Rheumatol. 2007 Jul;19(4):370-5. doi: 10.1097/BOR.0b013e328133f5c7.
8
[Secondary osteoporosis. Pathogenesis of glucocorticoid-induced osteoporosis].[继发性骨质疏松症。糖皮质激素性骨质疏松症的发病机制]
Clin Calcium. 2007 Feb;17(2):270-4.
9
[Drug therapy of secondary osteoporosis: glucocorticoid-induced osteoporosis].继发性骨质疏松症的药物治疗:糖皮质激素诱导的骨质疏松症
Nihon Rinsho. 2009 May;67(5):985-90.
10
[Active vitamin D3 therapy for gulucocorticoid-induced osteoporosis].活性维生素D3治疗糖皮质激素性骨质疏松症
Clin Calcium. 2006 Jul;16(7):1201-7.